Constance Pechura, Ph.D., Executive Director, is an accomplished senior manager with over 25 years experience in basic research, science policy, and philanthropy. Pechura’s training and early research career were focused in behavioral pharmacology and neuroanatomy. Following a post-doctoral position at the National Institute of Neurological Diseases and Stroke, Pechura spent ten years at the Institute of Medicine, National Academies of Science, five of those as Deputy Director or Director of the Board on Neuroscience and Behavioral Health where she directed development and conduct of multiple major policy studies in addiction and mental illness. Prior to joining TRI, she spent eight years at the Robert Wood Johnson Foundation where she directed major grant programs targeting depression in primary care, addiction treatment, community health leadership, minority medical faculty development, health policy, and others. At various points during her RWJ tenure, Pechura served as Leader for program staff teams responsible for grant making in addiction prevention and treatment and building human capital. In addition to her position at TRI, Dr. Pechura is an Adjunct Associate Professor of Neuroscience in Psychiatry at the University of Pennsylvania.

Rosalyn Weinstein, Associate Director of TRI since January 2000, has more than 24 years of clinical and management experience in the substance abuse and mental health fields. As Associate Director, Weinstein has worked with Dr. Pechura and other senior TRI administrators to lead the organization through periods of strategic expansion, where she has analyzed and matched growth opportunities and needs of the field against internal and external capabilities. Weinstein joined TRI in 1995 after seven years in senior management positions with the Philadelphia Child Guidance Center. Other senior positions include Executive Director of Interim House, a women’s residential treatment facility for recovering substance abusers, and consultancies with the Philadelphia-based Division of Substance Abuse at Thomas Jefferson University Hospital and the Coordinating Office of Drug and Alcohol Programs for the City of Philadelphia.

David Metzger, Ph.D, Since June, 2009 Dr. Metzger has been Scientific Liaison for TRI and the University of Pennsylvania’s (Penn) Department of Psychiatry, working to strengthen the collaboration between TRI and Penn through innovative research projects crossing several disciplines. In that capacity he brings a wealth of experience as Research Associate Professor and Director of the HIV/AIDS Prevention Research Division at the Penn Department of Psychiatry. He is also the Principal Investigator for the NIAID funded HIV Prevention Clinical Trials Unit in Philadelphia and the Director of the Social and Behavioral Sciences Core of the Penn Center for AIDS Research (CFAR). Since 1989, he and colleagues from the Center for Studies of Addiction have been conducting HIV-related longitudinal studies of injection and non-injection drug users, developing innovative community-based strategies for recruiting and retaining individuals at high risk of HIV infection into longitudinal studies of HIV prevention interventions. Currently, his work involves testing the safety and efficacy of behavioral and biomedical prevention interventions including preventive HIV vaccines, vaginal microbicides, social network interventions, and agonist drug treatment strategies in Philadelphia, Thailand and China. As chair of the NIH HIV Prevention Trials Network (HPTN) Substance Use Working Group for over six years, he helped design and lead the implementation of two large trials with sites in the United States, and Asia. He is currently Protocol Chair for the first randomized trial of drug treatment as HIV prevention (HPTN 058), being conducted among 1,500 heroin dependent injectors in Thailand and China. In June of 2007, he was the recipient of the NIDA International Program’s annual award for leadership in international research. In 2008, he was named a guest professor of the Wuhan Center for Disease Prevention and Control, in Wuhan, China.